What are the adverse reactions and therapeutic effects of the kras inhibitor sotoraxib?

Common adverse reactions of taking sotoracib include fatigue, liver toxicity and cough, nausea, diarrhea, musculoskeletal pain, etc.

The clinical efficacy of sotoracib is relatively good. A clinical study showed that the median response duration of patients with non-small cell lung cancer treated with sotoracib was 11.1 months, the median progression-free survival was 12.5 months, the objective response rate was 37.1%, and the disease control rate was 80.6%.

Soteracib drug introduction

is the first orally active G12C mutant KRAS inhibitor. Sotorasiib is indicated in multiple countries, including the European Union and the United States, for the treatment of advanced adult patients with previously treated KRAS G12C mutation-positive non-small cell lung cancer (NSCLC).

Adverse reactions of sotoracib

1. Gastrointestinal diseases: diarrhea, nausea, vomiting, constipation, abdominal pain.

2. Hepatobiliary system diseases: liver toxicity.

3. Respiratory system, chest and mediastinal diseases: cough, pneumonia, dyspnea.

4. Various musculoskeletal and connective tissue diseases: musculoskeletal pain, joint pain.

5. Systemic diseases and various reactions at the administration site: fatigue, edema, rash, maculopapular rash, dermatitis, and skin itching.

6. Laboratory abnormalities: increased alanine aminotransferase, increased aspartate aminotransferase, decreased calcium, decreased lymphocytes, decreased hemoglobin and sodium, increased alkaline phosphatase, and increased urinary protein.

Therapeutic efficacy of sotoraxib

Sotoraxib was compared with docetaxel in a randomized phase 3 trial in 345 patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

The study showed improved progression-free survival with sotoraxib (960 mg daily) compared with docetaxel (median progression-free survival, 5.6 months vs 4.5 months).

The radiographic response rate was 28.1% for sotoraxib and 13.2% for docetaxel.

Efficacy of Sotorracib

By irreversibly binding to KRASG12C, Sotorracib inhibits downstream signaling pathways related to cell growth and differentiation.

In the primary and updated analyzes of the Phase I/II CodeBreaK 100 trial, clinically relevant objective response rates were observed in patients with KRAS G12C mutation-positive non-small cell lung cancer. Additionally, clinically relevant duration of response was reported in an updated analysis of the trial. Sotorasiib had manageable tolerability, allowing dose adjustments to control toxicity.

In summary, sotorasiib is a promising KRASG12C inhibitor that may increase the available treatment options for patients with KRAS G12C mutation-positive NSCLC who have previously received platinum-based chemotherapy and/or immunotherapy.

Measures for treatment of adverse reactions of sotorasiib

1. Nausea: It is recommended that patients eat less greasy food, eat more light food, avoid spicy and irritating food, and eat small meals frequently.

2. Diarrhea: Patients with diarrhea should keep their abdomen warm and should not eat cold food to avoid aggravating diarrhea. If necessary, they can use antidiarrheal drugs such as montmorillonite powder as directed by the doctor.

3. Skin rash: After sotolaxib causes rash, you can use calamine lotion to relieve itching. Pay attention to skin care and wear loose and comfortable clothes. Drugs such as diphenhydramine and cetirizine can be used if necessary.

4. Elevated liver enzymes: During the use of sotoraxib, patients need to monitor liver function regularly. Once elevated liver enzymes are found, the drug needs to be suspended under the guidance of a doctor, or the treatment plan should be adjusted according to the degree of liver function damage, including giving hepatoprotective drugs.

Related hot article recommendations: